RCS - Redx Pharma plc - Redx to present preclinical data on RXC009 at ASN

Redx PharmaAnnouncement

30/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231030:nRSd6217Ra&default-theme=true

RNS Number : 6217R  Redx Pharma plc  30 October 2023

REDX PHARMA PLC

 

("Redx" or the "Company")

 

Redx to Present Preclinical Data on RXC009, a selective Discoidin Domain
Receptor 1 inhibitor

 

RXC009, recently nominated as Redx's latest development candidate, is a
potential first-in-class treatment for chronic kidney disease and associated
fibrosis

 

Alderley Park, UK, 30 October 2023 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, targeted therapeutics for the treatment of fibrotic disease and
cancer announces that it will present preclinical data from its
recently-nominated development candidate, RXC009 at the American Society of
Nephrology (ASN) Annual Meeting (2-5 November 2023, Philadelphia, PA).

 

Redx nominated RXC009 as a development candidate in October 2023. RXC009 is a
small molecule, orally available, highly potent and selective DDR1 inhibitor
and a potential first-in-class treatment for chronic kidney disease (CKD).

 

CKD affects 8% to 16% of the population worldwide and is most commonly
attributed to diabetes and hypertension. Renal fibrosis, characterized by
tubulointerstitial fibrosis and glomerulosclerosis, is one of the final
manifestations of CKD as it progresses and is associated with high
morbidity 1 .

 

DDRs have recently gained traction as druggable targets with the potential to
treat multiple fibrotic conditions, including kidney fibrosis associated with
CKD such as in Alport Syndrome, but to date, no selective inhibitors of DDR1
have entered the clinic.

 

Dr Nicolas Guisot, Vice President, Drug Discovery at Redx, will make an oral
presentation discussing preclinical data from studies of RXC009 in a validated
animal model of CKD.

Details of the presentation are as follows:

 

 Title: Development of Novel Selective DDR1 Inhibitors with the Potential to
 Treat CKD

 Day/Date: November 4, 2023

 Time: 4:48 - 4:57 pm

 Location: Room 103, Pennsylvania Convention Center

 

 For further information, please contact:

 Redx Pharma Plc                                                                T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)                                    T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                                 T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                                     T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                                 T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

 

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, targeted therapeutics
for the treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis, aiming initially to progress them to clinical
proof of concept before evaluating options for further development and
potential value creation. The Company's lead fibrosis product candidate, the
selective ROCK2 inhibitor, zelasudil (RXC007), is in development for
interstitial lung disease and is undergoing a Phase 2a trial for idiopathic
pulmonary fibrosis (IPF) with topline data expected in H1 2024. The Company's
second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the
treatment of fibrostenotic Crohn's disease, is progressing towards a CTA
application during the fourth quarter of 2023.  Redx's lead oncology product
candidate, the Porcupine inhibitor RXC004, being developed as a targeted
treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1
combination Phase 2 data during the first half of 2024, following which Redx
will seek a partner for ongoing development. In October 2023, Redx nominated
its next development candidate, RXC009 a highly potent and selective DDR1
inhibitor for the treatment of chronic kidney disease and associated fibrosis.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its wholly-owned clinical-stage
product candidates and discovery pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a
non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult
patients with mantle cell lymphoma previously treated with a covalent BTK
inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic
diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical
study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals,
which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now
progressing through Phase 1 clinical studies, and an early stage oncology
research collaboration.

 

To subscribe to Email Alerts from Redx, please
visit: www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/) .

 

 1  Taken in part from Chen TK et al; JAMA. 2019 Oct 1; 322(13): 1294Ð1304.
(https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=31573641)

(#_ftnref1)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFEDISLAFIV